(Reuters) – Eli Lilly and Co said on Friday it expects the U.S. Food and Drug Administration to decline the approval of expanded use of its rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.
“At this point, the company does not have alignment with the FDA on the indicated population,” the drugmaker said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
